Substituted Indole Compounds for TLR7 8 9 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases related to Toll-like receptor 7, 8, and 9 (TLR7, TLR8, TLR9) modulation are inadequate, as existing therapies fail to effectively inhibit sustained activation of these receptors, leading to exacerbation of disease states.
Innovation Solution
Development of substituted indole compounds that act as inhibitors of TLR7, TLR8, and TLR9 signaling, providing pharmaceutical compositions and methods for their use in treating proliferative, allergic, autoimmune, and inflammatory diseases by administering therapeutically effective amounts of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for TLR modulation, then treatment is provided, but they fail to effectively inhibit sustained activation of TLR7/8/9, leading to exacerbation of disease states
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula I) that have optimized pharmacological properties. The compounds feature varied substituents (R1-R6, A, G, n, p parameters) that can be tuned to achieve effective TLR7/8/9 inhibition while maintaining desired stability, bioavailability, and safety profiles, directly resolving the inadequacy of existing therapies
Solution Approach 2:
The invention employs composite molecular structures combining indole core with various heterocyclic groups and substituents. These composite compounds (e.g., combining indole with piperidinyl, morpholinyl, or other heterocycles) provide enhanced and selective TLR inhibition compared to simpler existing therapies, addressing the failure of current treatments to effectively inhibit sustained TLR activation
2Reliability
If substituted indole compounds are developed as TLR inhibitors, then effective inhibition of TLR7/8/9 signaling is achieved, but new pharmaceutical compositions and compounds must be created
Solution Approach 1:
The patent segments the TLR inhibition problem into targeting specific receptors (TLR7, TLR8, TLR9) with dedicated compound variants. Different embodiments of Formula (I) are optimized for selective inhibition of individual TLRs or combinations, allowing effective inhibition while managing structural complexity through modular design where core indole structure remains constant but substituents are varied for specific receptor targeting
3Adaptability or versatility
If new compounds are developed to modulate cytokine production and B cell activity, then therapeutic benefits are provided, but extensive structural variations and optimizations are required
Solution Approach 1:
The patent achieves universality by designing compounds of Formula (I) that can modulate multiple immune pathways simultaneously. The molecular structure is designed to inhibit TLR7/8/9 signaling, which in turn affects cytokine production and B cell activity across multiple disease conditions. This multi-functional approach allows a single compound class to address various autoimmune and inflammatory diseases (SLE, IBD, MS, RA, etc.), providing broad therapeutic applicability without requiring extensive separate structural optimizations for each indication
Data Source
AI summary
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.